GB2111052B - A process for preparing 3-hydroxy-ml-236b derivatives known as m-4 and m-4' - Google Patents

A process for preparing 3-hydroxy-ml-236b derivatives known as m-4 and m-4'

Info

Publication number
GB2111052B
GB2111052B GB08233267A GB8233267A GB2111052B GB 2111052 B GB2111052 B GB 2111052B GB 08233267 A GB08233267 A GB 08233267A GB 8233267 A GB8233267 A GB 8233267A GB 2111052 B GB2111052 B GB 2111052B
Authority
GB
United Kingdom
Prior art keywords
hydroxy
preparing
derivatives known
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB08233267A
Other languages
English (en)
Other versions
GB2111052A (en
Inventor
Akira Terahara
Minoru Tanaka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sankyo Co Ltd
Original Assignee
Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co Ltd filed Critical Sankyo Co Ltd
Publication of GB2111052A publication Critical patent/GB2111052A/en
Application granted granted Critical
Publication of GB2111052B publication Critical patent/GB2111052B/en
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/40—Preparation of oxygen-containing organic compounds containing a carboxyl group including Peroxycarboxylic acids
    • C12P7/42—Hydroxy-carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/02—Oxygen as only ring hetero atoms
    • C12P17/06—Oxygen as only ring hetero atoms containing a six-membered hetero ring, e.g. fluorescein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/62—Carboxylic acid esters
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/365—Nocardia
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/872—Nocardia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cardiology (AREA)
  • Veterinary Medicine (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
GB08233267A 1981-11-20 1982-11-22 A process for preparing 3-hydroxy-ml-236b derivatives known as m-4 and m-4' Expired GB2111052B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP56186641A JPS5889191A (ja) 1981-11-20 1981-11-20 ３−ヒドロキシ−ｍｌ−２３６ｂ誘導体の製造法

Publications (2)

Publication Number Publication Date
GB2111052A GB2111052A (en) 1983-06-29
GB2111052B true GB2111052B (en) 1985-05-09

Family

ID=16192138

Family Applications (1)

Application Number Title Priority Date Filing Date
GB08233267A Expired GB2111052B (en) 1981-11-20 1982-11-22 A process for preparing 3-hydroxy-ml-236b derivatives known as m-4 and m-4'

Country Status (18)

Country Link
US (1) US4537859A (enExample)
JP (1) JPS5889191A (enExample)
KR (1) KR880002483B1 (enExample)
AT (1) AT387585B (enExample)
AU (1) AU551720B2 (enExample)
BE (1) BE895080A (enExample)
CA (1) CA1186647A (enExample)
CH (1) CH651065A5 (enExample)
DE (1) DE3242849A1 (enExample)
DK (1) DK159328C (enExample)
ES (1) ES517542A0 (enExample)
FI (1) FI70925C (enExample)
FR (1) FR2516935A1 (enExample)
GB (1) GB2111052B (enExample)
IT (1) IT1191235B (enExample)
NL (1) NL194373C (enExample)
SE (1) SE453996B (enExample)
ZA (1) ZA828535B (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5451688A (en) * 1992-12-28 1995-09-19 Sankyo Company, Limited Hexahydronaphthalene ester derivatives, their preparation and their therapeutic uses
RU2114101C1 (ru) * 1993-01-29 1998-06-27 Санкио Компани Лимитед Эфирные производные гексагидронафталина, их получение и фармацевтическая композиция на их основе

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3682557D1 (de) * 1985-09-13 1992-01-02 Sankyo Co Hydroxy-ml-236b-derivate, deren herstellung und anwendung.
US5116870A (en) * 1986-06-23 1992-05-26 Merck & Co., Inc. HMG-CoA reductase inhibitors
USRE36481E (en) * 1986-06-23 2000-01-04 Merck & Co., Inc. HMG-CoA reductase inhibitors
US4940727A (en) * 1986-06-23 1990-07-10 Merck & Co., Inc. Novel HMG-CoA reductase inhibitors
US4833258A (en) * 1987-02-17 1989-05-23 Merck & Co., Inc. Intermediates useful in the preparation of HMG-COA reductase inhibitors
DE3869282D1 (de) * 1987-09-02 1992-04-23 Merck & Co Inc Inhibitoren von hmg-coa-reduktase.
US4997848A (en) 1987-10-27 1991-03-05 Sankyo Company, Limited Octahydronaphthalene oxime derivatives for cholesterol synthesis inhibition
EP0337548A3 (en) * 1988-04-15 1991-08-14 Merck & Co. Inc. HMG-COA reductase inhibitors produced by nocardia SP. (MA6455)(ATCC 53695)
US4997755A (en) * 1988-04-15 1991-03-05 Merck & Co., Inc. HMG-CoA reductase inhibitors produced by Nocardia sp. (MA 6455)
US4963538A (en) * 1988-06-29 1990-10-16 Merck & Co., Inc. 5-oxygenated HMG-CoA reductase inhibitors
US5001241A (en) * 1989-06-09 1991-03-19 Merck & Co., Inc. 3-KETO HMG-CoA reductase inhibitors
US4937259A (en) * 1989-06-09 1990-06-26 Merck & Co., Inc. Antihypercholesterolemic compounds
US4970231A (en) * 1989-06-09 1990-11-13 Merck & Co., Inc. 4-substituted HMG-CoA reductase inhibitors
US5041562A (en) * 1989-06-09 1991-08-20 Merck & Co., Inc. 3-keto HMG-CoA reductase inhibitors
US5010105A (en) * 1989-06-09 1991-04-23 Merck & Co., Inc. Antihypercholesterolemic compounds
US4965200A (en) * 1989-06-23 1990-10-23 Merck & Co., Inc. Process for the preparation of 3-keto, 5-hydroxy simvastatin analogs
US4997849A (en) * 1989-06-23 1991-03-05 Merck & Co., Inc. Microbial transformation of simvastatin
US5112857A (en) * 1990-09-04 1992-05-12 Merck & Co., Inc. Hmg-coa reductase inhibitor metabolites
US6043064A (en) * 1993-10-22 2000-03-28 Bristol-Myers Squibb Company Enzymatic hydroxylation process for the preparation of HMG-CoA reductase inhibitors and intermediates thereof
US5942423A (en) * 1995-06-07 1999-08-24 Massachusetts Institute Of Technology Conversion of compactin to pravastatin by actinomadura
SI9800144A (sl) 1998-05-21 1999-12-31 LEK, tovarna farmacevtskih in kemičnih izdelkov, d.d. Nov biotehnološki postopek pridobivanja 3-hidroksi-ML-236B derivatov poznanih kot M-4 in M-4'
SI20305A (sl) * 1999-08-06 2001-02-28 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Kristali natrijeve soli pravastatina
DE60034547T8 (de) 1999-01-20 2008-04-30 Kyowa Hakko Kogyo Co., Ltd. Verfahren zur herstellung von hemmern der hmg-coa reduktase
WO2000044886A1 (en) * 1999-01-29 2000-08-03 Kyowa Hakko Kogyo Co., Ltd. PROCESS FOR PRODUCING HMG-CoA REDUCTASE INHIBITOR
US6682913B1 (en) * 1999-02-03 2004-01-27 Institute For Drug Research Ltd. Microbial process for preparing pravastatin
HUP9902352A1 (hu) 1999-07-12 2000-09-28 Gyógyszerkutató Intézet Kft. Eljárás pravasztatin mikrobiológiai előállítására
HRP20030347A2 (en) * 2000-10-05 2005-04-30 Teva Gy�gyszergy�r R�szv�nyt�rsas�g Pravastatin sodium substantially free of pravastatin lactone and epi-pravastatin, and compositions containing same
JP3236282B1 (ja) * 2000-10-16 2001-12-10 三共株式会社 プラバスタチンを精製する方法
JP2003093045A (ja) * 2001-09-26 2003-04-02 Godo Shusei Co Ltd 有用変換微生物
WO2003088900A2 (en) * 2002-04-16 2003-10-30 Merck & Co., Inc. Solid forms of salts with tyrosine kinase activity
RU2217141C1 (ru) * 2002-11-20 2003-11-27 Балавадзе Михаил Элизбарович Состав "витализин-1" для профилактики атеросклероза, сердечно-сосудистых заболеваний и поддерживающей терапии вирусных заболеваний
US20040198800A1 (en) * 2002-12-19 2004-10-07 Geoffrey Allan Lipoxygenase inhibitors as hypolipidemic and anti-hypertensive agents
CA2508840A1 (en) 2002-12-20 2004-07-08 Pfizer Products Inc. Dosage forms comprising a cetp inhibitor and an hmg-coa reductase inhibitor
US20040132771A1 (en) * 2002-12-20 2004-07-08 Pfizer Inc Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
KR100470078B1 (ko) * 2003-06-12 2005-02-04 씨제이 주식회사 컴팩틴을 프라바스타틴으로 전환할 수 있는 스트렙토마이세스 종(Ｓｔｒｅｐｔｏｍｙｃｅｓ ｓｐ.)ＣＪＰＶ 975652 및 그를 이용한 프라바스타틴의 제조방법
CN1839114A (zh) 2003-08-21 2006-09-27 默克弗罗斯特加拿大有限公司 组织蛋白酶半胱氨酸蛋白酶抑制剂
US20050101927A1 (en) * 2003-09-11 2005-05-12 Kimberly-Clark Worldwide, Inc. Absorbent products comprising a moisturizing and lubricating composition
CA2546601A1 (en) 2003-11-19 2005-06-09 Metabasis Therapeutics, Inc. Novel phosphorus-containing thyromimetics
TWI252253B (en) * 2004-01-09 2006-04-01 Chinese Petroleum Corp A novel Pseudonocardia sp RMRC PAH4 and a process for bioconverting compactin into pravastatin using the same
KR100637762B1 (ko) * 2004-07-30 2006-10-23 주식회사 지니스 저콜레스테롤 란을 생산하기 위한 가금류용 사료첨가제 및 이를 이용한 저콜레스테롤 란의 생산방법
US20110217412A1 (en) * 2004-07-30 2011-09-08 Jinis Biopharmaceuticals Co. Cholesterol lowering supplement and low cholesterol egg produced by using the same
TWI307360B (en) 2004-12-03 2009-03-11 Teva Gyogyszergyar Zartkoruen Mukodo Reszvenytarsasag Process for constructing strain having compactin hydroxylation ability
EP1827421B1 (en) 2004-12-09 2017-09-27 Merck Sharp & Dohme Corp. Estrogen receptor modulators
CN104188952A (zh) 2005-03-02 2014-12-10 默沙东公司 抑制组织蛋白酶k的组合物
WO2006123182A2 (en) 2005-05-17 2006-11-23 Merck Sharp & Dohme Limited Cyclohexyl sulphones for treatment of cancer
PE20070427A1 (es) * 2005-08-30 2007-04-21 Novartis Ag Compuestos derivados de benzimidazoles sustituidos como inhibidores de tirosina quinasas
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
PE20080359A1 (es) 2006-04-19 2008-06-06 Novartis Ag Compuestos de benzoxazol y benzotiazol 6-0-sustituidos y metodos de inhibicion de la senalizacion de csf-1r
AU2007300627B2 (en) 2006-09-22 2012-02-16 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
GEP20115337B (en) 2007-01-10 2011-11-25 St Di Ricerche Di Biologia Molecolare P Angeletti Spa Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors
EA019951B1 (ru) 2007-03-01 2014-07-30 Новартис Аг Ингибиторы киназы pim и способы их применения
CA2685967A1 (en) 2007-05-21 2008-11-21 Novartis Ag Csf-1r inhibitors, compositions, and methods of use
AU2008269154B2 (en) 2007-06-27 2014-06-12 Merck Sharp & Dohme Llc 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
ES2413504T3 (es) 2007-12-21 2013-07-16 Ligand Pharmaceuticals Inc. Moduladores selectivos del receptor de andrógeno (SARM) y usos de los mismos
CN102016054A (zh) * 2008-04-25 2011-04-13 株式会社太平洋 用生物转化系统制备正二羟基异黄酮的方法
WO2010093601A1 (en) 2009-02-10 2010-08-19 Metabasis Therapeutics, Inc. Novel sulfonic acid-containing thyromimetics, and methods for their use
WO2010114780A1 (en) 2009-04-01 2010-10-07 Merck Sharp & Dohme Corp. Inhibitors of akt activity
MY174452A (en) 2009-10-14 2020-04-19 Schering Corp Substituted piperidines that increase p53 activity and the uses thereof
US8999957B2 (en) 2010-06-24 2015-04-07 Merck Sharp & Dohme Corp. Heterocyclic compounds as ERK inhibitors
US8518907B2 (en) 2010-08-02 2013-08-27 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA)
EP3587574B1 (en) 2010-08-17 2022-03-16 Sirna Therapeutics, Inc. Rna interference mediated inhibition of hepatitis b virus (hbv) gene expression using short interfering nucleic acid (sina)
US8883801B2 (en) 2010-08-23 2014-11-11 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
US8946216B2 (en) 2010-09-01 2015-02-03 Merck Sharp & Dohme Corp. Indazole derivatives useful as ERK inhibitors
US9242981B2 (en) 2010-09-16 2016-01-26 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel ERK inhibitors
US9260471B2 (en) 2010-10-29 2016-02-16 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA)
EP2654748B1 (en) 2010-12-21 2016-07-27 Merck Sharp & Dohme Corp. Indazole derivatives useful as erk inhibitors
EP2675440B1 (en) 2011-02-14 2020-03-25 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
CA2833009A1 (en) 2011-04-21 2012-10-26 Merck Sharp & Dohme Corp. Insulin-like growth factor-1 receptor inhibitors
US9023865B2 (en) 2011-10-27 2015-05-05 Merck Sharp & Dohme Corp. Compounds that are ERK inhibitors
EP3919620A1 (en) 2012-05-02 2021-12-08 Sirna Therapeutics, Inc. Short interfering nucleic acid (sina) compositions
JP6280554B2 (ja) 2012-09-28 2018-02-14 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｅｒｋ阻害剤である新規化合物
DK2925888T3 (en) 2012-11-28 2017-12-18 Merck Sharp & Dohme COMPOSITIONS AND METHODS OF CANCER TREATMENT
AR094116A1 (es) 2012-12-20 2015-07-08 Merck Sharp & Dohme Imidazopiridinas sustituidas como inhibidores de hdm2
WO2014120748A1 (en) 2013-01-30 2014-08-07 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
US20160194368A1 (en) 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Circular polynucleotides
WO2015051479A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
KR20160065854A (ko) 2013-10-08 2016-06-09 머크 샤프 앤드 돔 코포레이션 카텝신 시스테인 프로테아제 억제제
EP3613418A1 (en) 2014-01-17 2020-02-26 Ligand Pharmaceuticals, Inc. Methods and compositions for modulating hormone levels
WO2015120580A1 (en) 2014-02-11 2015-08-20 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
JO3589B1 (ar) 2014-08-06 2020-07-05 Novartis Ag مثبطات كيناز البروتين c وطرق استخداماتها
EP3525785B1 (en) 2016-10-12 2025-08-27 Merck Sharp & Dohme LLC Kdm5 inhibitors
EP3706747B1 (en) 2017-11-08 2025-09-03 Merck Sharp & Dohme LLC Prmt5 inhibitors
US10947234B2 (en) 2017-11-08 2021-03-16 Merck Sharp & Dohme Corp. PRMT5 inhibitors
WO2020033284A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
EP3833355A4 (en) 2018-08-07 2022-05-11 Merck Sharp & Dohme Corp. PRMT5 INHIBITORS
US11993602B2 (en) 2018-08-07 2024-05-28 Merck Sharp & Dohme Llc PRMT5 inhibitors
BR112021020864A2 (pt) 2019-04-19 2021-12-14 Ligand Pharm Inc Formas cristalinas e métodos de produção de formas cristalinas de um composto
WO2021126729A1 (en) 2019-12-17 2021-06-24 Merck Sharp & Dohme Corp. Prmt5 inhibitors
US20230108114A1 (en) 2019-12-17 2023-04-06 Merck Sharp & Dohme Llc Prmt5 inhibitors
AU2020408148B2 (en) 2019-12-17 2025-04-24 Merck Sharp & Dohme Llc PRMT5 inhibitors
AU2024228641A1 (en) 2023-03-02 2025-07-24 Carcimun Biotech Gmbh Means and methods for diagnosing cancer and/or an acute inflammatory disease
WO2025147589A1 (en) 2024-01-05 2025-07-10 Osanni Bio, Inc. Implants, compositions, and methods for treating retinal diseases and disorders

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3281330A (en) * 1964-03-20 1966-10-25 Upjohn Co Microbiological process for the oxygenation of cycloalkanes
US3392171A (en) * 1964-03-20 1968-07-09 Upjohn Co 4-morpholino-4'-hydroxy bicyclohexyls
DK149080C (da) * 1980-06-06 1986-07-28 Sankyo Co Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5451688A (en) * 1992-12-28 1995-09-19 Sankyo Company, Limited Hexahydronaphthalene ester derivatives, their preparation and their therapeutic uses
RU2114101C1 (ru) * 1993-01-29 1998-06-27 Санкио Компани Лимитед Эфирные производные гексагидронафталина, их получение и фармацевтическая композиция на их основе

Also Published As

Publication number Publication date
CH651065A5 (de) 1985-08-30
SE8206580D0 (sv) 1982-11-18
SE8206580L (sv) 1983-05-21
DK159328C (da) 1991-02-25
BE895080A (fr) 1983-03-16
FI70925B (fi) 1986-07-18
AU9061082A (en) 1983-05-26
FI823978L (fi) 1983-05-21
IT8268359A0 (it) 1982-11-22
ES8402350A1 (es) 1984-01-16
NL194373C (nl) 2002-02-04
JPH0371116B2 (enExample) 1991-11-12
DK516182A (da) 1983-05-21
FI823978A0 (fi) 1982-11-19
KR880002483B1 (ko) 1988-11-19
FR2516935A1 (fr) 1983-05-27
ES517542A0 (es) 1984-01-16
US4537859A (en) 1985-08-27
ATA425182A (de) 1988-07-15
DE3242849C2 (enExample) 1989-01-05
JPS5889191A (ja) 1983-05-27
AT387585B (de) 1989-02-10
IT1191235B (it) 1988-02-24
DE3242849A1 (de) 1983-06-01
NL194373B (nl) 2001-10-01
KR840002451A (ko) 1984-07-02
AU551720B2 (en) 1986-05-08
CA1186647A (en) 1985-05-07
FR2516935B1 (enExample) 1985-02-08
FI70925C (fi) 1986-10-27
DK159328B (da) 1990-10-01
SE453996B (sv) 1988-03-21
ZA828535B (en) 1983-10-26
GB2111052A (en) 1983-06-29
NL8204505A (nl) 1983-06-16

Similar Documents

Publication Publication Date Title
GB2111052B (en) A process for preparing 3-hydroxy-ml-236b derivatives known as m-4 and m-4'
PL250524A1 (en) Process for preparing derivatives of 2,2'-imino-bisethanol
PT73757B (en) Process for preparing n-thiazolylmethylthioalkyl-n'- -alkylamidines and related compounds
HUT35639A (en) Process for preparing 3-chloro-1-formyl-4-phenyl-pyrrole derivatives
HUT38941A (en) Process for preparing triazolo-quinazoline derivatives
HUT38093A (en) Process for preparing benzene-sulphonamide derivatives
HUT38317A (en) Process for preparing ethylene-diamino-monoamide derivatives
HUT39479A (en) Process for preparing 4'-dechloro-rebeccamicin
PH18444A (en) 28-deoxy-3' ,5' -di-o-alkylcarbonyl-5-fluorouridine derivatives,a process for the preparation of the derivatives and anti-tumor agents containing the derivatives
HUT38604A (en) Process for preparing fluoro-alkyl-amine derivatives
PL235180A1 (en) Process for preparing novel derivatives of 4a,9b-transhexahydro-1h-pyridoindole and 2,3,4,5-tetrahydro-1h-pyridoindole
HUT38333A (en) Process for preparing 1-piperidino-2-phenyl-quinoline derivatives
HUT40114A (en) Process for preparing flavolignane derivatives
PL235949A1 (en) Process for preparing derivatives of 2,3,4-trinor-1,5-inter-m-phenyleneprostacyclin
RO93563B (ro) Procedeu de preparare a unor derivati de 3-fenoxifenil-propen-1-il-ciclopropan
DE3260876D1 (en) 4-isopropyl-4'-nitrobenzophenone and process for preparing it
EP0350292A3 (en) Process for preparing 2'-deoxy-beta-adenosine
HUT37757A (en) Process for preparing 2-substituted-5-methyl-pyridina derivatives
GB8800425D0 (en) Process for preparing 4 4-dialkyl-2-azetidinones
DE3169609D1 (en) Process for preparing m,m'-dinitrobenzophenone
GB2157287B (en) Process for preparing 3-exomethylenecepham derivatives
PT80104A (en) Process for preparing 1,2,4-triazacycloalkadiene derivatives
GB2155921B (en) Process for producing 4-alkyl-4'-formylbiphenyl
PL237908A1 (en) Process for preparing derivatives of 5/6/-phenylsulfonyloxybenzimidazole
MY8700182A (en) Process for preparing 16 alpha -hydorxy-17 alpha- aminopregnane derivatives

Legal Events

Date Code Title Description
PE20 Patent expired after termination of 20 years

Effective date: 20021121